Research funding, conflicts of interest, and the "meta-methodology" of public relations

Public Health Reports

Volumn 117, Issue 4, 2002, Pages 331-339

  Rampton, Sheldon ^a   Stauber, John ^a  

^a Center for Media and Democracy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEMOGRAPHY; FINANCIAL MANAGEMENT; MARKETING; METHODOLOGY; PERCEPTION; PRIORITY JOURNAL; PSYCHOLOGY; PUBLIC RELATIONS; RELIABILITY; RESEARCH; REVIEW;

EID: 0036664544     PISSN: 00333549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-3549(04)50169-3     Document Type: Editorial

References (37)

1. Rose M. Activism in the 90s: changing roles for public relations. Public Relations Quarterly 1991; 36(3):28-32.
2. Rothenberg R. The age of spin. Esquire 1996 Dec:71.
3. Hanners D. Scientists were paid to write letters: tobacco industry sought to discredit EPA report. St. Louis Pioneer Dispatch 1998 Aug 4.
4. Ornstein C. Fen-phen maker accused of funding journal articles. Dallas Morning News 1999 May 23; Sect A:1.
5. Authors' correspondence with Norman Bauman. See also: Bauman N. Medical writers get $300-$700/day working for drug companies. 1991 Apr 1 [cited 2001 Dec 12]. Available from: URL: http://www.nasw.org /users/nbauman/ghost.htm as well as Burton R. Selling drugs - with a little help from a journalist. British Medical Journal 2001;323:1258.
6. Authors' correspondence with Norman Bauman. See also: Bauman N. Medical writers get $300-$700/day working for drug companies. 1991 Apr 1 [cited 2001 Dec 12]. Available from: URL: http://www.nasw.org /users/nbauman/ghost.htm as well as Burton R. Selling drugs - with a little help from a journalist. British Medical Journal 2001;323:1258.
7. Bell R. Impure science: fraud, compromise and political influence in scientific research. New York: John Wiley & Sons, Inc.; 1992. p. 190-219.
8. Mossman BT, Gee JB. Asbestos-related diseases. New Engl J Med 1989;320:1721-30. For a detailed critique of this incident, see Brodeur P, Ravanesi B. Old tricks. The Networker (newsletter of the Science and Environmental Health Network); 1998 Jun.
9. Mossman BT, Gee JB. Asbestos-related diseases. New Engl J Med 1989;320:1721-30. For a detailed critique of this incident, see Brodeur P, Ravanesi B. Old tricks. The Networker (newsletter of the Science and Environmental Health Network); 1998 Jun.
10. For NEJM's response to the controversy over this incident, see Angell M, KassirerJP. Editorials and Conflicts of Interest. New Engl J Med 1996;335:1055-6. For the researchers' side, see Manson JE. Adventures in scientific discourse. Epidemiology 1997;8:324-7.
11. For NEJM's response to the controversy over this incident, see Angell M, KassirerJP. Editorials and Conflicts of Interest. New Engl J Med 1996;335:1055-6. For the researchers' side, see Manson JE. Adventures in scientific discourse. Epidemiology 1997;8:324-7.
12. Berke JH. Living downstream. New Engl J Med 1997; 337:1562.
13. Medical journal apologizes for ethics blunder. Washington Post 1997 Dec 28.
14. Krimsky S, Rothenberg LS, Stott P, Kyle G. Scientific journals and their authors' financial interests: a pilot study. Psychother Psychosom 1998;67(4-5):194-201.
15. King RT, Medical journals rarely disclose researchers' ties, drawing ire. Wall Street Journal 1999 Feb 2. See also Krimsky S. Will disclosure of financial interests brighten the image of entrepreneurial science? Boyd CJ, editor. 1999 AAAS Annual Meeting and Science Innovation Exposition: Challenges for a New Century. Abstract A-29. American Association for the Advancement of Science.
16. King RT, Medical journals rarely disclose researchers' ties, drawing ire. Wall Street Journal 1999 Feb 2. See also Krimsky S. Will disclosure of financial interests brighten the image of entrepreneurial science? Boyd CJ, editor. 1999 AAAS Annual Meeting and Science Innovation Exposition: Challenges for a New Century. Abstract A-29. American Association for the Advancement of Science.
17. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. New Engl J Med 1992;327:1135-40.
18. Rampton S, Stauber J. Trust us, we're experts: how industry manipulates science and gambles with your future. New York: Tarcher/Putnam; 2001. p. 204-15.
19. U.S. expenditures for research and development by source of funds and performer. Wall Street Journal Almanac 1999. New York: Ballantine Books; 1998. p. 363.
20. Industry trends in research support and links to public research. National Science Board; 1998 [cited 2000 Jul 25]. Available from: URL: http://www.nsf.gov/pubs/1998/nsb9899/nsb9899.htm
21. Robinson MB. Medical school faculty say budget cuts are hurting teaching. Associated Press; 1999 May 19.
22. Collaborations between business and academia are mediated by groups such as the Business-Higher Education Forum, a partnership of the American Council on Education and the National Alliance of Business, as well as the Government-University-Industry Research Roundtable (GUIRR), established in 1984 and sponsored by the National Academy of Sciences, the National Academy of Engineering and the Institute of Medicine, in order to "convene senior-most representatives from government, universities, and industry to define and explore critical issues related to the national science and technology agenda." For examples of some of these collaborations, see Press E, Washburn J. The kept university. Atlantic; 2000 March.
23. Michaelson M. Remarks delivered at AAAS symposium on Secrecy in Science; 1999 Mar 29; MIT, Cambridge, MA. Available from: URL: http://www.aaas.org/spp/secrecy/Presents/michael.htm [cited 2000 Jul 25].
24. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science. JAMA 1997;277:1224-8.
25. Benowitz S. Is corporate research funding leading to secrecy in science? The Scientist 1996;10:1, 6-7.
26. Rennie D. Thyroid storm. JAMA 1997;277:1242.
27. Shenk D. Money + science = ethics problems on campus. The Nation 1999; 22 Mar:11-12.
28. Thompson J, Baird P, Downie J. Report of the committee of inquiry on the case involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex, Inc. Canadian Association of University Teachers, 2001 [cited 2001 Dec 10]. Available from: URL: http://www.caut.ca/english/issues/acadfreedom /olivieri.asp
29. Hotz RL. Secrecy is often the price of medical research funding. Los Angeles Times 1999 May 18; Sect. A:1.
30. Knox RA. Disclosure fight may push doctor out of occupational health field. Boston Globe 1999 May 22; Sect. B:5.
31. Special report: what happens when universities become businesses? Research Corporation Annual Report, 1997. p. 9.
32. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturersupported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Int Med 1994;154:15-763. The study looked at all randomized control trials of nonsteroidal anti-inflammatory drugs used in the treatment of arthritis, based on a MEDLINE search between the dates of September 1987 and May 1990. "Researchers, 'blinded' to manufacturer status, evaluated the narrative interpretation of results and extracted numeric data on efficacy and toxicity." For both efficacy and toxicity, the question of whether trial data supported the study's conclusions was answered by defining "adequate documentation as being the reporting of a test of statistical significance (p≤0.05) for one or more comparisons."
33. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Int Med 1996;124:485-9.
34. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel zantagonists. New Engl J Med 1998;338:101-6.
35. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282:1453-7.
36. Fagin D, Lavelle M. Toxic deception. Secaucus (NJ): Birch Lane Press; 1996. p. 51-2.
37. Journals fail to adhere to guidelines on conflicts of interest. BMJ 2001;323:651.